Jäger Dirk, Taverna Christian, Zippelius Alfred, Knuth Alexander
Klinik und Poliklinik für Onkologie, Universitätsspital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Cancer Immunol Immunother. 2004 Mar;53(3):144-7. doi: 10.1007/s00262-003-0470-z. Epub 2004 Jan 15.
The presence of tumor infiltrating T cells has been shown to be associated with a favorable prognosis in different tumor types. Several strategies have been developed to identify relevant tumor antigens which can be used for active immunotherapy strategies. The SEREX technique (serological analysis of cDNA expression libraries) identifies tumor antigens based on a spontaneous humoral immune response in cancer patients. This technique is not limited to tumor types that can be grown in cell culture or depends on established T cell clones recognizing the autologous tumor. Several steps of analysis are mandatory to evaluate SEREX-defined antigens before they become new target antigens for active immunotherapy: expression analysis; serological analysis with sera from tumor patients and normal individuals; identification of potential peptide epitopes for CD8 T cells and evaluation in T cell assays. This article summarizes our approach of antigen identification and evaluation giving the example of the recently cloned breast cancer antigen NY-BR-1.
肿瘤浸润性T细胞的存在已被证明与不同肿瘤类型的良好预后相关。已经开发了几种策略来鉴定可用于主动免疫治疗策略的相关肿瘤抗原。SEREX技术（cDNA表达文库的血清学分析）基于癌症患者的自发体液免疫反应来鉴定肿瘤抗原。该技术不限于可在细胞培养中生长的肿瘤类型，也不依赖于识别自体肿瘤的已建立T细胞克隆。在SEREX定义的抗原成为主动免疫治疗的新靶抗原之前，必须进行几个分析步骤来评估它们：表达分析；用肿瘤患者和正常个体的血清进行血清学分析；鉴定CD8 T细胞的潜在肽表位并在T细胞试验中进行评估。本文以最近克隆的乳腺癌抗原NY-BR-1为例，总结了我们的抗原鉴定和评估方法。
